Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Significance of Soluble Interleukin-2 Receptor to Predict Prognosis and Support Decision-Making on Watchful Waiting for Stage II-IV Follicular Lymphoma Patients in the Rituximab Era

Tsuyoshi Muta, MD, Takeshi Okatani, MD, Mitsuhiro Itagaki, MD, Yoshimasa Suetsugu, MD, Masaaki Noda, MD, Tasuya Terasaki, MD, Yu Kochi, MD, Fumiaki Jinnouchi, MD, Tatsuji Mino, Ryota Imanaka, MD, Kohei Kyo, MD, Yuta Katayama, MD PhD, Shinya Katsutani, MD PhD, Koji Iwato, MD PhD, Hideki Asaoku, MD

Blood (2018) 132 (Supplement 1): 5321.

https://doi.org/10.1182/blood-2018-99-116016

Published: 2018

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Melphalan and Low-Dose Total Body Irradiation: A Single Center Analysis

Tatsuji Mino, Yuta Katayama, MD PhD, Tatsuya Terasaki, MD, Yu Kochi, MD, Fumiaki Jinnouchi, MD, Takeshi Okatani, MD, Ryota Imanaka, MD, Kohei Kyo, MD, Mitsuhiro Itagaki, MD, Shinya Katsutani, MD PhD, Tsuyoshi Muta, MD, Koji Iwato, MD PhD, Hideki Asaoku, MD

Blood (2018) 132 (Supplement 1): 2095.

https://doi.org/10.1182/blood-2018-99-113461

Published: 2018

Journal Articles

Comparison of Reduced-Intensity Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Patients 50 Years or Older

Koji Kawamura, MD, Shinichi Kako, MD, Shuichi Mizuta, MD PhD, Ken Ishiyama, MD PhD, Jun Aoki, MD, Shingo Yano, MD PhD, Takahiro Fukuda, MD, Naoyuki Uchida, MD PhD, Yukiyasu Ozawa, MD PhD, Tetsuya Eto, MD PhD, Koji Iwato, MD, Tatsuo Ichinohe, MD PhD, Yoshiko Atsuta, MD PhD, Yoshinobu Kanda, MD PhD

Blood (2016) 128 (22): 3414.

https://doi.org/10.1182/blood.V128.22.3414.3414

Published: 2016

Journal Articles

Impact of the Presence of HLA 1-Locus Mismatch and the Use of Thymoglobulin in Unrelated Bone Marrow Transplantation

Koji Kawamura, MD, Junya Kanda, MD, Shigeo Fuji, MD, Kosuke Yoshioka, MD, Yukiyasu Ozawa, MD PhD, Takahiro Fukuda, MD, Naoyuki Uchida, MD PhD, Koji Iwato, MD, Tatsuo Ichinohe, MD PhD, Yoshiko Atsuta, MD PhD, Yoshinobu Kanda, MD PhD

Blood (2016) 128 (22): 4688.

https://doi.org/10.1182/blood.V128.22.4688.4688

Published: 2016

Journal Articles

A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management

Ryota Imanaka, MD, Taiichi Kyo, MD, Kayo Toishigawa, MD, Tetsuro Ochi, MD, Takeshi Okatani, MD, Kouhei Kyo, MD, Mitsuhiro Itagaki, MD, Hisao Nagoshi, MD, Yuta Katayama, MD PhD, Koji Iwato, MD, Hideki Asaoku, MD

Blood (2015) 126 (23): 2500.

https://doi.org/10.1182/blood.V126.23.2500.2500

Published: 2015

Journal Articles

Donor Cell-Derived Hematologic Malignancy: A Survey of Complication Working Group of the Japan Society for Hematopoietic Cell Transplantation

Motohiro Kato, MD PhD, Takuya Yamashita, MD PhD, Ritsuro Suzuki, MD PhD, Kimikazu Matsumoto, MD PhD, Hisakazu Nishimori, Satoshi Takahashi, MD, Koji Iwato, MD, Chiaki Nakaseko, MD PhD, Tadakazu Kondo, MD, Kazunori Imada, Fumihiko Kimura, MD, Tatsuo Ichinohe, MDPhD, Yoshiko Hashii, MD PhD, Koji Kato, MD PhD, Yoshiko Atsuta, MDPhD, Shuichi Taniguchi, MD PhD, Takahiro Fukuda, MD

Blood (2015) 126 (23): 859.

https://doi.org/10.1182/blood.V126.23.859.859

Published: 2015

Journal Articles

Efficacy of High-Dose Cytarabine Added to Cyclophosphamide/Total-Body Irradiation in the Conditioning Regimen of Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancy

Yasuyuki Arai, MD, Kazunari Aoki, MD, June Takeda, MD, Tadakazu Kondo, MD, Tetsuya Eto, MD PhD, Shuichi Ota, MD, Hisako Hashimoto, MD, Takahiro Fukuda, MD, Yukiyasu Ozawa, MD, Yoshinobu Kanda, MD PhD, Chiaki Kato, MD, Mineo Kurokawa, MD, Koji Iwato, MD, Makoto Onizuka, MD, Tatsuo Ichinohe, MD, Yoshiko Atsuta, MDPhD, Akiyoshi Takami, MD

Blood (2015) 126 (23): 734.

https://doi.org/10.1182/blood.V126.23.734.734

Published: 2015

Journal Articles

Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation

Michiko Kida, MDPhD, Kensuke Usuki, MDPhD, Naoyuki Uchida, MDPhD, Takahiro Fukuda, MD, Koji Iwato, MD, Ken-ichi Matsuoka, MDPhD, Tetsuya Eto, MD PhD, Tatsuo Ichinohe, MDPhD, Yoshiko Atsuta, MDPhD, Minoko Takanashi, MD PhD, Akiyoshi Takami, MD PhD, Yasushi Miyazaki, MD PhD, Shingo Yano, MDPhD, Ken Ishiyama, MD PhD

Blood (2015) 126 (23): 4371.

https://doi.org/10.1182/blood.V126.23.4371.4371

Published: 2015

Journal Articles

Title in Chemotherapy for Acute Myeloid Leukemia with High Leukocyte Counts.

Taiichi Kyo, MD, Ryota Imanaka, MD, Tetsuro Ochi, MD, Takeshi Okatani, MD, Kohei Kyo, MD, Mitsuhiro Itagaki, MD, Hisao Nagoshi, MD, Yuta Katayama, MD, Koji Iwato, MD, Hideki Asaoku, MD

Blood (2014) 124 (21): 5272.

https://doi.org/10.1182/blood.V124.21.5272.5272

Published: 2014

Journal Articles

Treatment of AML with Myelodysplasia Related Changes(AML-MRC) By Sequential Therapy of Azacitidine (AZA) and Intensive Chemotherapy

Taiichi Kyo, MD, Kouhei Kyo, MD, Kayo Toishikawa, MD, Ryota Imanaka, MD, Tetsuro Ochi, MD, Yuta Katayama, MD, Takeshi Okatani, MD, Mitsuhiro Itagaki, MD, Koji Iwato, MD, Hideki Asaoku, MD

Blood (2014) 124 (21): 5288.

https://doi.org/10.1182/blood.V124.21.5288.5288

Published: 2014

Journal Articles

Hepatitis B and C Virus Infections Are Not Associated With Worse Clinical Outcomes After Autologous Stem Cell Transplantation: On Behalf Of The Adult Lymphoma Working Group Of The Japan Society For Hematopoietic Cell Transplantation (JSHCT)

Harumi Kato, MD, PhD, Dai Chihara, MD, PhD, Koji Kato, MD, PhD, Sung-Won Kim, MD, PhD, Takehiko Mori, MD, PhD, Masashi Sawa, MD, PhD, Yuki Ohno, MD, PhD, Hisako Hashimoto, M.D., Ph.D., Masayuki Hino, MD, PhD, Koji Iwato, MD, PhD, Takaaki Chou, MD, PhD, Hisashi Sakamaki, MD, PhD, Ritsuro Suzuki, MD, PhD, Junji Suzumiya, MD, PhD

Blood (2013) 122 (21): 4270.

https://doi.org/10.1182/blood.V122.21.4270.4270

Published: 2013

Journal Articles

Improvement Of The Efficacy Of Azacitidine At a Fixed Dosing Schedule Of 75mg/m 2 /Day For 5 Days, Followed By 21 Days Drug-Off In Higher Risk Myelodysplastic Syndromes

Taiichi Kyo, M.D., Kouhei Kyo, MD, Ryouta Imanaka, M.D., Mitsuhiro Itagaki, MD, Tetsuro Ochi, Takeshi Okatani, M.D., Koji Iwato, MD, Yuta Katayama, MD, PhD, Hideki Asaoku, M.D.

Blood (2013) 122 (21): 1571.

https://doi.org/10.1182/blood.V122.21.1571.1571

Published: 2013

Journal Articles

Treatment Results of Intensive Chemotherapy for Higher-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia Related to MDS (MDS-AML)

Taiichi Kyo, MD, Noriaki Yoshida, MD, Kouhei Kyo, MD, Takeshi Okatani, MD, Mitsuhiro Itagaki, MD, Hiromi Yuasa, MD, Koji Iwato, MD, Hideki Asaoku, MD, Yuuta Katayama, MD

Blood (2010) 116 (21): 2934.

https://doi.org/10.1182/blood.V116.21.2934.2934

Published: 2010

Journal Articles

Evaluation of Romiplostim In a Randomized Placebo-Controlled Phase 3 Study of a Japanese Population with Chronic Immune Thrombocytopenia (ITP).

Koji Miyazaki, MD, Yukari Shirasugi, MD, Kiyoshi Ando, MD, PhD, Yoshiaki Tomiyama, MD, Shinichiro Okamoto, MD, PhD, Mineo Kurokawa, MD, Keita Kirito, MD, Yuji Yonemura, MD, PhD, Shinichiro Mori, MD, Kensuke Usuki, MD, PhD, Koji Iwato, MD, PhD, Satoshi Hashino, MD, PhD, Helen Wei, PhD, Richard Lizambri, MD

Blood (2010) 116 (21): 3704.

https://doi.org/10.1182/blood.V116.21.3704.3704

Published: 2010

Journal Articles

High Remission Rates and Long-Term Survival in a High Percentage of Patients Achieved by Intensive Chemotherapy for AML and Further Improvement of Supportive Care.

Taiichi Kyo, MD, Akiko Kimura, MD, Kouhei Kyo, MD, Noriaki Yoshida, MD, Hideki Asaoku, MD, Koji Iwato, MD, Yuuta Katayama, MD, Hiromi Yuasa, MD

Blood (2009) 114 (22): 1052.

https://doi.org/10.1182/blood.V114.22.1052.1052

Published: 2009

Journal Articles

Clinical Outcome by Acute Graft-Versus Host Disease (GVHD) Prophylaxis in Patients Underwent Allogeneic Bone Marrow Transplantation from Unrelated Donors: Nationwide Survey in Japan.

Masamichi Hara, MD, Toshio Wakayama, MD, Hiroatsu Ago, MD, Teruhiko Kozuka, MD, Yuichiro Nawa, MD, Koji Iwato, MD, Hiroshi Sao, MD, Shinichiro Okamoto, MD, Hisashi Sakamaki, MD, Takakazu Kawase, MD, Yasuo Morishima, MD, Yoshihisa Kodera, MD

Blood (2007) 110 (11): 1960.

https://doi.org/10.1182/blood.V110.11.1960.1960

Published: 2007

NARROW

Significance of Soluble Interleukin-2 Receptor to Predict Prognosis and Support Decision-Making on Watchful Waiting for Stage II-IV Follicular Lymphoma Patients in the Rituximab Era

Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Melphalan and Low-Dose Total Body Irradiation: A Single Center Analysis

Comparison of Reduced-Intensity Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Patients 50 Years or Older

Impact of the Presence of HLA 1-Locus Mismatch and the Use of Thymoglobulin in Unrelated Bone Marrow Transplantation

A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management

Donor Cell-Derived Hematologic Malignancy: A Survey of Complication Working Group of the Japan Society for Hematopoietic Cell Transplantation

Efficacy of High-Dose Cytarabine Added to Cyclophosphamide/Total-Body Irradiation in the Conditioning Regimen of Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancy

Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation

Title in Chemotherapy for Acute Myeloid Leukemia with High Leukocyte Counts.

Treatment of AML with Myelodysplasia Related Changes(AML-MRC) By Sequential Therapy of Azacitidine (AZA) and Intensive Chemotherapy

Hepatitis B and C Virus Infections Are Not Associated With Worse Clinical Outcomes After Autologous Stem Cell Transplantation: On Behalf Of The Adult Lymphoma Working Group Of The Japan Society For Hematopoietic Cell Transplantation (JSHCT)

Improvement Of The Efficacy Of Azacitidine At a Fixed Dosing Schedule Of 75mg/m 2 /Day For 5 Days, Followed By 21 Days Drug-Off In Higher Risk Myelodysplastic Syndromes

Treatment Results of Intensive Chemotherapy for Higher-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia Related to MDS (MDS-AML)

Evaluation of Romiplostim In a Randomized Placebo-Controlled Phase 3 Study of a Japanese Population with Chronic Immune Thrombocytopenia (ITP).

High Remission Rates and Long-Term Survival in a High Percentage of Patients Achieved by Intensive Chemotherapy for AML and Further Improvement of Supportive Care.

Clinical Outcome by Acute Graft-Versus Host Disease (GVHD) Prophylaxis in Patients Underwent Allogeneic Bone Marrow Transplantation from Unrelated Donors: Nationwide Survey in Japan.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only